{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:05:01Z","timestamp":1792641901169,"version":"4.5.0"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Topical antibacterials are commonly used for superficial pyodermas such as impetigo and treatment or prevention of infections following minor cuts, abrasions, burns, and surgical wounds. Several antibiotics and antiseptics are available for use in different indications. One of the major uses of topical antibacterials is acne in which benzoyl peroxide is the drug of the first choice either singly or in combination with antibiotics or retinoids. Mupirocin and fusidic acid are the two most commonly used antibiotics for the treatment of superficial pyodermas and eradication of staphylococcal carrier state. Bacterial resistance to topical antibiotics is a growing concern and topical antiseptics such as gentian violet are getting renewed interest as alternatives. Incidence of contact dermatitis is a limiting factor for the use of several topical antibacterials. Although many botanical products have demonstrated\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      activities against skin pathogens, their clinical utilities remain to be established by good-quality clinical trials.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_99_18","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T12:52:07Z","timestamp":1623156727000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":69,"title":["Topical Antibacterials in Dermatology"],"prefix":"10.4103","volume":"66","author":[{"given":"Debabrata","family":"Bandyopadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20240829","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1529-8019.2008.00190.x","article-title":"Local antibiotics in dermatology","volume":"21","author":"Gelmetti","year":"2008","journal-title":"Dermatol Ther"},{"key":"R2-1-20240829","first-page":"72","article-title":"Antibiotic ointment in the treatment of Grover disease","volume":"80","author":"Julliard","year":"2007","journal-title":"Cutis"},{"key":"R3-1-20240829","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0190-9622(08)80206-X","article-title":"Fusidic acid cream in the treatment of plasma cell balanitis","volume":"27","author":"Petersen","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"R4-1-20240829","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0190-9622(96)90865-8","article-title":"Plasma cell gingivitis: Treatment with 2% fusidic acid","volume":"34","author":"Mahler","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R5-1-20240829","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1468-3083.2007.02557.x","article-title":"Successful treatment of confluent and reticulated papillomatosis with topical mupirocin","volume":"22","author":"Gonul","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R6-1-20240829","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1086\/644732","article-title":"Topical antimicrobial therapy for treating chronic wounds","volume":"49","author":"Lipsky","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R7-1-20240829","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.clindermatol.2016.10.010","article-title":"Topical treatments for acne","volume":"35","author":"Kosmadaki","year":"2017","journal-title":"Clin Dermatol"},{"key":"R8-1-20240829","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0149-2918(98)80076-3","article-title":"Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients","volume":"20","author":"Lowe","year":"1998","journal-title":"Clin Ther"},{"key":"R9-1-20240829","first-page":"370","article-title":"L. Local treatment of acne. A double-blind study and valuation of the effect of different concentrations of benzoyl peroxide gel","volume":"1","author":"Lassus","year":"1987","journal-title":"Curr Med Res Oin"},{"key":"R10-1-20240829","first-page":"265","article-title":"Comparison of 2 clindamycin 1%-benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris","volume":"83","author":"Dhawan","year":"2009","journal-title":"Cutis"},{"key":"R11-1-20240829","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaad.2008.06.040","article-title":"An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients","volume":"59","author":"Thiboutot","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R12-1-20240829","first-page":"899","article-title":"Long-term safety and efficacy of a unique fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% for the treatment of acne vulgaris","volume":"6","author":"Pariser","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"R13-1-20240829","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jamadermatol.2017.1297","article-title":"Antibiotic resistance in acne treatment","volume":"1538","author":"Adler","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R14-1-20240829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40257-016-0242-0","article-title":"Dapsone 7.5% gel: A review in acne vulgaris","volume":"18","author":"Al-Salama","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"R15-1-20240829","first-page":"553","article-title":"Efficacy and safety of once-daily dapsone gel, 7.5% for treatment of adolescents and adults with acne vulgaris: First of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Stein Gold","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"R16-1-20240829","first-page":"962","article-title":"Efficacy and safety of once-daily dapsone gel 7.5% for treatment of adolescents and adults with acne vulgaris: Second of two identically designed, large, multicenter, randomized, vehicle-controlled trials","volume":"15","author":"Eichenfield","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"R17-1-20240829","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1684\/ejd.2010.0833","article-title":"Fusidic acid in dermatology: An updated review","volume":"20","author":"Sch\u00f6fer","year":"2010","journal-title":"Eur J Dermatol"},{"key":"R19-1-20240829","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/026921638900300412","article-title":"The use of metronidazole gel to control the smell of malodorous lesions","volume":"3","author":"Newman","year":"1989","journal-title":"Palliat Med"},{"key":"R21-1-20240829","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000081032","article-title":"Activity of nadifloxacin (OPC-7251) and seven other antimicrobial agents against aerobic and anaerobic Gram-positive bacteria isolated from bacterial skin infections","volume":"50","author":"Nenoff","year":"2004","journal-title":"Chemotherapy"},{"key":"R22-1-20240829","first-page":"48","article-title":"Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: A double-blind, phase III comparison study versus erythromycin 2% cream","volume":"16","author":"Plewig","year":"2006","journal-title":"Eur J Dermatol"},{"key":"R23-1-20240829","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1517\/14656566.7.14.1957","article-title":"Nadifloxacin: A quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771","volume":"7","author":"Jacobs","year":"2006","journal-title":"Expert Opin Pharmacother"},{"key":"R24-1-20240829","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1128\/AAC.00184-06","article-title":"Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes","volume":"50","author":"Yan","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-1-20240829","doi-asserted-by":"crossref","first-page":"a027110","DOI":"10.1101\/cshperspect.a027110","article-title":"Pleuromutilins: Potent drugs for resistant bugs\u2014mode of action and resistance","volume":"7","author":"Paukner","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R26-1-20240829","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.01568-15","article-title":"In vitro activity of retapamulin and antimicrobial susceptibility patterns in a longitudinal collection of methicillin-resistant staphylococcus aureus isolates from a veterans affairs medical center antimicrob","volume":"60","author":"Harrington","year":"2016","journal-title":"Agents Chemother"},{"key":"R27-1-20240829","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/jac\/dkm019","article-title":"In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections","volume":"59","author":"Odou","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"R28-1-20240829","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1365-2133.2008.08485.x","article-title":"Efficacy and safety of retapamulin ointment as treatment of impetigo: Randomized double-blind multicentre placebo-controlled trial","volume":"158","author":"Koning","year":"2008","journal-title":"Br J Dermatol"},{"key":"R29-1-20240829","first-page":"620","article-title":"Topical antibacterial agents for wound care: A Primer","volume":"29","author":"Spann","year":"2003","journal-title":"Dermatol Surg"},{"key":"R30-1-20240829","first-page":"51","article-title":"Silver sulfadiazine: A review of the evidence","volume":"1","author":"White","year":"2005","journal-title":"Wounds UK"},{"key":"R31-1-20240829","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s41038-017-0096-6","article-title":"Topical antimicrobial agents for pediatric burns","volume":"5","author":"Cartotto","year":"2017","journal-title":"Burns Trauma"},{"key":"R32-1-20240829","first-page":"5","article-title":"Matrix metalloproteinases in normal and impaired wound healing: A potential role of nanocrystalline silver","volume":"13","author":"Kirsner","year":"2002","journal-title":"Wounds"},{"key":"R33-1-20240829","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/CMR.12.1.147","article-title":"Antiseptics and disinfectants: Activity, action, and resistance","volume":"12","author":"McDonnell","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"R34-1-20240829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.idc.2010.11.001","article-title":"Hand Hygiene","volume":"25","author":"Bolon","year":"2011","journal-title":"Infect Dis Clin N Am"},{"key":"R35-1-20240829","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/CMR.00112-16","article-title":"Current and emerging topical antibacterials and antiseptics: Agents, action, and resistance patterns","volume":"30","author":"Williamson","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"R36-1-20240829","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.ajic.2016.04.235","article-title":"Chlorhexidine avoids skin bacteria recolonization more than triclosan","volume":"44","author":"Macias","year":"2016","journal-title":"Am J Infect Control"},{"key":"R37-1-20240829","doi-asserted-by":"crossref","first-page":"87S","DOI":"10.1111\/j.1365-2672.1996.tb04837.x","article-title":"Activity of biocides against mycobacteria","volume":"81","author":"Russell","year":"1996","journal-title":"J Appl Bacteriol Symp"},{"key":"R38-1-20240829","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ijsu.2017.06.001","article-title":"Preoperative chlorhexidine versus povidone-iodine antisepsis for preventing surgical site infection: A meta-analysis and trial sequential analysis of randomized controlled trials","volume":"44","author":"Zhang","year":"2017","journal-title":"Int J Surg"},{"key":"R39-1-20240829","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/bja\/aen324","article-title":"Anaphylaxis to the chlorhexidine component of Instillagel: A case series","volume":"102","author":"Parkes","year":"2009","journal-title":"Br J Anaesth"},{"key":"R40-1-20240829","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/exd.12257","article-title":"Gentian violet: A 19th century drug re-emerges in the 21st century","volume":"22","author":"Maley","year":"2013","journal-title":"J Exp Dermatol"},{"key":"R41-1-20240829","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1046\/j.1365-4362.2000.00128.x","article-title":"Topical gentian violet for cutaneous infection and nasal carriage with MRSA","volume":"39","author":"Okano","year":"2000","journal-title":"Int J Dermatol"},{"key":"R42-1-20240829","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaad.2009.05.027","article-title":"A nonsteroidal alternative to impetiginized eczema in the emergency room","volume":"63","author":"Stoff","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"R43-1-20240829","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.det.2010.08.009","article-title":"Effectiveness of gentian violet and similar products commonly used to treat pyodermas","volume":"29","author":"Berrios R","year":"2011","journal-title":"Dermatol Clin"},{"key":"R44-1-20240829","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/1756-0500-6-272","article-title":"Co-operative inhibitory effects of hydrogen peroxide and iodine against bacterial and yeast species","volume":"6","author":"Zubko","year":"2013","journal-title":"BMC Res Notes"},{"key":"R45-1-20240829","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/030079903125001523","article-title":"Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild-to-moderate acne vulgaris: A randomised, controlled trial versus benzoyl peroxide gel","volume":"192","author":"Milani","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"R46-1-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D39RP912J2","article-title":"Topical iodophor preparations: Chemistry, microbiology, and clinical utility","volume":"18","author":"Capriotti","year":"2012","journal-title":"Dermatol Online J"},{"key":"R47-1-20240829","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/0002-9610(86)90477-0","article-title":"Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions","volume":"151","author":"Zamora","year":"1986","journal-title":"Am J Surg"},{"key":"R48-1-20240829","doi-asserted-by":"crossref","first-page":"521","DOI":"10.12968\/jowc.2016.25.9.521","article-title":"Enhanced wound healing by topical application of ointment containing a low concentration of povidone-iodine","volume":"25","author":"Mitani","year":"2016","journal-title":"J Wound Care"},{"key":"R49-1-20240829","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/28970","article-title":"Triclosan targets lipid synthesis","volume":"394","author":"McMurry","year":"1998","journal-title":"Nature"},{"key":"R50-1-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-6968.2001.tb10772.x","article-title":"Triclosan: A widely used biocide and its link to antibiotics","volume":"202","author":"Schweizer","year":"2001","journal-title":"FEMS Microbiol Lett"},{"key":"R51-1-20240829","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1128\/AAC.02105-16","article-title":"Triclosan: An instructive tale","volume":"60","author":"McNamara","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"R52-1-20240829","first-page":"586","article-title":"In-vitro anti-bacterial and anti-fungal activity of select essential oils","volume":"6","author":"Soni","year":"2014","journal-title":"Int J Pharm Pharm Sci"},{"key":"R53-1-20240829","first-page":"247","article-title":"Botanicals in dermatology an evidence-based review","volume":"11","author":"Reuter Reuter","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"R54-1-20240829","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.foodchem.2014.10.042","article-title":"Plants belonging to the genus Thymus as antibacterial agents: From farm to pharmacy","volume":"173","author":"Nabavi","year":"2015","journal-title":"Food Chem"},{"key":"R55-1-20240829","first-page":"1","article-title":"Antibacterial effect of neem oil on methicillin resistant Staphylococcus aureus","volume":"41","author":"Gupta","year":"2016","journal-title":"J Med Plant Stud"},{"key":"R56-1-20240829","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s40257-016-0247-8","article-title":"Honey and wound healing: An update","volume":"18","author":"Saikaly","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"R57-1-20240829","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.burns.2016.07.004","article-title":"The effects of honey compared to silver sulfadiazine for the treatment of burns: A systematic review of randomized controlled trials","volume":"43","author":"Aziz","year":"2017","journal-title":"Burns"},{"key":"R58-1-20240829","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/pds.1117","article-title":"Contact allergy to neomycin sulfate: Results of a multifactorial analysis","volume":"14","author":"Menezes de P\u00e1dua","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R59-1-20240829","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1046\/j.1365-2133.2002.04662.x","article-title":"Comparative frequency of patch test reactions to topical antibiotics","volume":"146","author":"Morris","year":"2002","journal-title":"Br J Dermatol"},{"key":"R60-1-20240829","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0536.2006.01084.x","article-title":"Contact allergy to topical medicaments becomes more common with advancing age: An age-stratified study","volume":"56","author":"Green","year":"2007","journal-title":"Contact Dermatitis"},{"key":"R61-1-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2007.07.050","article-title":"Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management","volume":"58","author":"Gehrig","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"R62-1-20240829","first-page":"12","article-title":"A look at the safety of metronidazole 1% gel: Cumulative irritation, contact sensitization, phototoxicity, and photoallergy potential","volume":"77","author":"Beutner","year":"2006","journal-title":"Cutis"},{"key":"R63-1-20240829","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2310\/6620.2004.04009","article-title":"Prevalence of botanical extract allergy in patients with contact dermatitis","volume":"15","author":"Simpson","year":"2004","journal-title":"Dermatitis"},{"key":"R64-1-20240829","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.clinthera.2014.04.003","article-title":"Susceptibility of staphylococcus aureus to topical agents in the United States: A sentinel study","volume":"36","author":"Biedenbach","year":"2014","journal-title":"Clin Ther"},{"key":"R65-1-20240829","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1128\/CMR.00112-16","article-title":"Current and emerging topical antibacterials and antiseptics: Agents, action, and resistance patterns","volume":"30","author":"Williamson","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"R66-1-20240829","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1128\/AAC.02707-13","article-title":"Decreased Susceptibilities to retapamulin, mupirocin, and chlorhexidine among staphylococcus aureus isolates causing skin and soft tissue infections in otherwise healthy children","volume":"58","author":"McNeil","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R67-1-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15310\/2334-3591.1065","article-title":"Bacterial development of resistance to botanical antimicrobials","volume":"2","author":"Ruiz","year":"2017","journal-title":"J Evol Health"},{"key":"R68-1-20240829","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/jac\/45.4.549","article-title":"Selection of resistance to the essential oil of Melaleuca alternifolia in Staphylococcus aureus","volume":"45","author":"Nelson","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"R69-1-20240829","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1525-1470.2011.01700.x","article-title":"Bacterial resistance and impetigo treatment trends: A review","volume":"29","author":"Bangert","year":"2012","journal-title":"Pediatr Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_99_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:06:58Z","timestamp":1787771218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_99_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_99_18","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}